Target intelligence / Profile preview

Fibroblast growth factor 3 (FGF3)

Target
FGF3
Molecular classification
Growth factor, Secreted signaling protein
01

Overview

Fibroblast growth factor 3 (FGF3) is a member of the FGF family, which comprises secreted signaling proteins essential for cell growth, proliferation, differentiation, and development. FGF3 is especially critical in embryonic development, where it triggers chemical signals influencing the formation and maturation of structures such as the inner and outer ears and teeth. Mutations in FGF3 are linked to congenital disorders, notably causing deafness and dental malformations (LAMM syndrome). FGF3 also possesses oncogenic potential due to its proto-oncogene classification, and aberrant expression may be implicated in certain cancers[6].

Other names
FGF-3INT2INT-2 proto-oncogene proteinHBGF-3Heparin-binding growth factor 3Proto-oncogene Int-2V-INT2 murine mammary tumor virus integration site oncogene homolog
02

Mechanism of action

Drugs that target the FGF/FGFR pathway (such as FGFR inhibitors) typically act by blocking the receptor's kinase activity or ligand binding to inhibit downstream signaling, though these do not target FGF3 directly[7].

03

Biological functions

Regulation of cell growthCell proliferationCell maturationAngiogenesis (formation of blood vessels)Wound healingEmbryonic development (especially ear and tooth formation)
04

Disease associations

Cancer (proto-oncogene/oncogenic potential)Congenital deafness with labyrinthine aplasia, microtia, and microdontia (as seen in LAMM syndrome)
05

Safety considerations

Potential oncogenic activity due to proto-oncogene statusDisruption may cause developmental disorders (particularly affecting ear and tooth formation)
06

Interacting drugs

No approved or specific drugs directly targeting FGF3; current therapies mainly target fibroblast growth factor receptors (FGFRs) rather than the FGF ligands themselves[7].
07

Biomarkers

Mutational analysis of FGF3 for congenital deafness syndromes (such as LAMM syndrome)[6].Proto-oncogene expression in tumorigenesis (potential biomarker in certain cancers).

Beyond the preview

Go deeper on Fibroblast growth factor 3 (FGF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fibroblast growth factor 3 (FGF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call